Cynata Therapeutics (CYP) Q3 2025 TU earnings summary

Executive summary

• Ended March 2025 quarter with AUD 8.5 million in cash, providing runway through mid-2026 and supporting major clinical readouts for GvHD and osteoarthritis trials.

• Advanced clinical pipeline includes osteoarthritis (phase III), GvHD (phase II), diabetic foot ulcers (phase I complete), and kidney transplantation (phase I/II recruiting).

• Published peer-reviewed data highlighting Cymerus MSCs' superior immunomodulatory and wound healing properties.

• Two programs (osteoarthritis and kidney transplantation) are externally funded and partnered, with commercial rights retained.

• No changes in substantial holders; share price stable compared to start of quarter.

Financial highlights

• Cash balance of AUD 8.5 million at quarter end, sufficient for operations through to mid-2026 and to cover upcoming clinical milestones.

• Net operating cash outflows for the quarter were $2.1 million.

• Net cash from financing activities was $102k for the quarter, with $7.6m raised year-to-date.

• Market capitalisation: ~A$44 million as of 2 May 2025.

• No outstanding loan or credit facilities at quarter end.

Outlook and guidance

• GvHD phase II trial enrollment expected to complete by July 2025, with primary results anticipated late 2025.

• Osteoarthritis phase III trial results expected in H1 2026.

• Kidney transplantation trial cohort 1 enrollment expected to complete in the current quarter, with results in 2025.

• Ongoing engagement with potential partners and preparations for commercialization as major trial readouts approach.

• Cash runway expected to last into mid-2026.